WA Therapeutics Accelerator presents - From Bench to Batch

From bench to batch: planning early for commercial production of therapeutics
A promising compound is only the start. Before a therapy reaches patients, someone has to make it reliably, at scale and to regulatory standards. Investors and partners will ask how you plan to do that, often earlier than researchers expect.
This free workshop covers the scientific, technical and operational challenges of moving from laboratory discovery to commercial manufacturing, and the choices you can make now to avoid costly delays later. Topics include:
What a contract development and manufacturing organisation (CDMO) does, and chemistry, manufacturing and controls (CMC) in plain terms
The issues that most often slow down or derail technology transfer, and how to avoid them at discovery
What to consider for small molecules, nucleotides and biologics
Tools that carry through from the research lab to commercial scale, and the IP and freedom-to-operate questions to ask
A panel reality check on cost, timelines and Australia’s manufacturing track record
Speakers
Brett Alderson – BioCina
Dr Nicolas Pichon – Cytiva
Dr Samantha South – Patrys Limited
Dr James Williams - CEO, HTG
The morning ends with networking and a small-group (limited places) tour of BioCina’s manufacturing facility. Closed shoes are required for the tour.
Who should attend: WA researchers developing therapeutics, research commercialisation staff and early career researchers.